CDC issues guidance on prioritizing new RSV treatment for infants
The Centers for Disease Control and Prevention Oct. 23 released interim guidance for clinicians with limited access to the monoclonal antibody nirsevimab, recently approved to prevent respiratory syncytial virus in children aged 2 and under. The guidance calls for prioritizing 100 milligram doses of the treatment for infants under 6 months old and infants at high risk for severe disease due to underlying health conditions, among other recommendations.
Related News Articles
Headline
Health care organizations can create more inclusive, responsive and effective maternal health initiatives that address the unique challenges Black women…
Blog
Black women in the U.S. experience maternal mortality rates at nearly three times that of white women, regardless of income or education level. This…
Headline
Given the pressures of parenting, learn how health care organizations are supporting new moms to enable them to thrive at work, and most importantly, at home,…
Headline
Mounting pressures on the health care workforce have created a crisis with short-term staffing shortages and a long-range picture of an unfulfilled talent…
Headline
Cardiovascular conditions are one of the most common causes of morbidity and mortality among pregnant women. AHA’s Better Health for Mothers and Babies…
Headline
Kittitas Valley Healthcare in rural Washington state last year implemented an innovative new model for retaining essential obstetric and other women’s health…